Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 19, 2022

Primary Completion Date

August 9, 2024

Study Completion Date

January 17, 2025

Conditions
Celiac Disease
Interventions
DRUG

DONQ52

Subcutaneous (SC) injection

DRUG

Placebo

Subcutaneous (SC) injection

Trial Locations (21)

2560

Campbelltown Hospital, Campbelltown

4506

University of Sunshine Coast Clinical Trials Centre - Morayfield, Morayfield

6009

Linear Clinical Research, Nedlands

10019

Columbia University Medical Center, New York

11023

Long Island Gastrointestinal Research Group, Great Neck

27607

North Carolina Clinical Research, Raleigh

28557

Lucas Research - Diabetes & Endocrinology Consultants, PC, Morehead City

29621

Velocity Clinical Research, Anderson, Anderson

32216

Jacksonville Center for Clinical Research, Jacksonville

32789

Clinical Site Partners - Orlando, Winter Park

34748

Clinical Site Partners, Leesburg

36207

Pinnacle Research Group, Anniston

37920

Alliance for Multispecialty Research, Knoxville

43213

Aventiv Research, Inc., Columbus

45414

Digestive Specialists Inc, Dayton

55095

Mayo Clinic - Rochester, Rochester

70072

Tandem Clinical Research, Marrero

76712

Digestive Research of Central Texas, Waco

80209

Mountain View Clinical Research, Denver

83642

Velocity Clinical Research - Boise, Meridian

84403

Care Access Research, Ogden

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY